Display options
Cite
Didangelos TP, Athyros VG, Karamitsos DT, et al. Effect of aldose reductase inhibition on heart rate variability in patients with severe or moderate diabetic autonomic neuropathy. Clin Drug Investig. 1998;15(2):111-21doi: 10.2165/00044011-199815020-00005.
Didangelos, T. P., Athyros, V. G., Karamitsos, D. T., Papageorgiou, A. A., Kourtoglou, G. I., & Kontopoulos, A. G. (1998). Effect of aldose reductase inhibition on heart rate variability in patients with severe or moderate diabetic autonomic neuropathy. Clinical drug investigation, 15(2), 111-21. https://doi.org/10.2165/00044011-199815020-00005
Didangelos, T P, et al. "Effect of aldose reductase inhibition on heart rate variability in patients with severe or moderate diabetic autonomic neuropathy." Clinical drug investigation vol. 15,2 (1998): 111-21. doi: https://doi.org/10.2165/00044011-199815020-00005
Didangelos TP, Athyros VG, Karamitsos DT, Papageorgiou AA, Kourtoglou GI, Kontopoulos AG. Effect of aldose reductase inhibition on heart rate variability in patients with severe or moderate diabetic autonomic neuropathy. Clin Drug Investig. 1998;15(2):111-21. doi: 10.2165/00044011-199815020-00005. PMID: 18370475.
Copy Download .nbib Format: NLM
Share it on

Clin Drug Investig. 1998;15(2):111-21. doi: 10.2165/00044011-199815020-00005.

Effect of aldose reductase inhibition on heart rate variability in patients with severe or moderate diabetic autonomic neuropathy.

Clinical drug investigation

T P Didangelos, V G Athyros, D T Karamitsos, A A Papageorgiou, G I Kourtoglou, A G Kontopoulos

Affiliations

  1. Division of Diabetology, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece.

PMID: 18370475 DOI: 10.2165/00044011-199815020-00005

Abstract

Patients with diabetic autonomic neuropathy (DAN) have an increased cardiovascular mortality rate compared with diabetic patients without DAN. Heart rate variability (HRV) time and frequency domain indices are strong predictors of malignant arrhythmias and sudden cardiac death. This prospective, randomised, double-blind, placebo-controlled study analysed the long-term effect of an aldose reductase inhibitor, tolrestat, on HRV time and frequency domain variables in 45 patients with diabetes mellitus (DM) and DAN. Patients were randomised into tolrestat (n = 22) and placebo (n = 23) groups. Tolrestat (200 mg/day) or placebo were administered, respectively, for a period of 12 months. HRV was assessed at months 0, 3, 6, 9 and 12. The HRV level of the 45 patients was compared with that of 20 patients with DM, with analogous glycaemic control, without DAN and 20 healthy controls, of similar age and gender. At the twelfth month, tolrestat, compared with placebo, had a beneficial effect on HRV indices related to vagal tone. Compared with baseline, HRV time and frequency domain indices showed no significant improvement. Moreover, at the twelfth month of tolrestat administration, HRV indices remained less than that of patients with DM but without DAN, and healthy controls. The 12 patients of the 22 with moderate DAN benefited more than the 10 patients of the 22 with severe DAN. At the twelfth month no patient showed deterioration in HRV indices with tolrestat as was seen with placebo. Our data suggest that tolrestat slows down the progression of DAN compared with placebo. This effect of an aldose reductase inhibitor may contribute to a reduction in risk for malignant ventricular arrhythmias. The early detection of DAN is imperative for successful intervention.

References

  1. Am J Cardiol. 1987 Dec 1;60(16):1239-45 - PubMed
  2. Am J Cardiol. 1986 Feb 1;57(4):232-7 - PubMed
  3. Eur Heart J. 1996 Mar;17(3):354-81 - PubMed
  4. Am J Cardiol. 1996 Feb 1;77(4):242-6 - PubMed
  5. Diabetes Metab Rev. 1994 Dec;10(4):339-83 - PubMed
  6. Diabetes Metab Rev. 1995 Oct;11(3):193-225 - PubMed
  7. J Auton Nerv Syst. 1988 Aug;23(2):143-53 - PubMed
  8. Diabete Metab. 1990 Jul-Aug;16(4):296-302 - PubMed
  9. Metabolism. 1986 Apr;35(4 Suppl 1):96-100 - PubMed
  10. J Diabetes Complications. 1992 Apr-Jun;6(2):123-30 - PubMed
  11. Diabetes Care. 1995 Sep;18(9):1314-7 - PubMed
  12. Ann Intern Med. 1995 Apr 15;122(8):561-8 - PubMed
  13. Diabetologia. 1985 Jun;28(6):323-9 - PubMed
  14. Diabetes Metab Rev. 1988 May;4(3):255-71 - PubMed
  15. Diabetes Res Clin Pract. 1987 Nov;4(1):67-75 - PubMed
  16. Ann Intern Med. 1993 Mar 15;118(6):436-47 - PubMed
  17. Diabetes Res Clin Pract. 1991 Oct;14(1):63-73 - PubMed
  18. Diabetes Metab Rev. 1995 Oct;11(3):227-57 - PubMed
  19. Q J Med. 1990 Jun;75(278):635-46 - PubMed
  20. Diabetes Care. 1995 Apr;18(4):536-41 - PubMed
  21. Diabetes Res Clin Pract. 1995 May;28(2):103-17 - PubMed
  22. Q J Med. 1991 Jun;79(290):495-502 - PubMed
  23. Ann Intern Med. 1993 Jan 1;118(1):7-11 - PubMed
  24. Q J Med. 1980 Winter;49(193):95-108 - PubMed
  25. Diabetes Care. 1997 Mar;20(3):355-61 - PubMed

Publication Types